Reproducibility and Crossplatform Validation of Reverse-Phase Protein Array Data.

Reverse-phase protein array (RPPA) technology is a high-throughput antibody- and microarray-based approach for the rapid profiling of levels of proteins and protein posttranslational modifications in biological specimens. The technology consumes small amounts of samples, can sensitively detect low-abundance proteins and posttranslational modifications, enables measurements of multiple signaling pathways in parallel, has the capacity to analyze large sample numbers, and offers robust interexperimental reproducibility. These features of RPPA experiments have motivated and enabled the use of RPPA technology in various biomedical, translational, and clinical applications, including the delineation of molecular mechanisms of disease, profiling of druggable signaling pathway activation, and search for new prognostic markers. Owing to the complexity of many of these applications, such as developing multiplex protein assays for diagnostic laboratories or integrating posttranslational modification-level data using large-scale proteogenomic approaches, robust and well-validated data are essential. There are many distinct components of an RPPA workflow, and numerous possible technical setups and analysis parameter options exist. The differences between RPPA platform setups around the world offer opportunities to assess and minimize interplatform variation. Crossplatform validation may also aid in the evaluation of robust, platform-independent protein markers of disease and response to therapy.

[1]  S. Nock,et al.  Recent developments in protein microarray technology. , 2003, Angewandte Chemie.

[2]  Emanuel F Petricoin,et al.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays , 2003, Proteomics.

[3]  N. Carragher,et al.  Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. , 2017, Drug discovery today. Technologies.

[4]  G. Mills,et al.  An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays , 2012, Proteome Science.

[5]  Krister Wennerberg,et al.  Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach , 2017, Bioinform..

[6]  Emma Lundberg,et al.  A proposal for validation of antibodies , 2016, Nature Methods.

[7]  Keith A. Baggerly,et al.  Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots , 2012, Cancer informatics.

[8]  K. Baggerly,et al.  Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. , 2014, The oncologist.

[9]  Jaakko Astola,et al.  Nonlinear modeling of protein expressions in protein arrays , 2006, IEEE Transactions on Signal Processing.

[10]  E. Petricoin,et al.  Improved reproducibility of reverse‐phase protein microarrays using array microenvironment normalization , 2009, Proteomics.

[11]  P. Sorger,et al.  Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays , 2013, Oncogene.

[12]  L. Hood,et al.  The building blocks of successful translation of proteomics to the clinic , 2018, Current opinion in biotechnology.

[13]  John Austin,et al.  Contact printing of protein microarrays. , 2011, Methods in molecular biology.

[14]  E. Petricoin,et al.  Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer , 2017, Clinical Cancer Research.

[15]  E. Petricoin,et al.  Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. , 2014, Journal of proteome research.

[16]  Emanuel F Petricoin,et al.  Preparation and Use of Reverse Protein Microarrays , 2014, Current protocols in protein science.

[17]  S. Kingsmore.  Multiplexed protein measurement: technologies and applications of protein and antibody arrays , 2006, Nature Reviews Drug Discovery.

[18]  K. Rajapakshe,et al.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer , 2016, Oncogene.

[19]  Andreas Zell,et al.  RPPApipe: A pipeline for the analysis of reverse-phase protein array data , 2014, Biosyst..

[20]  Bin Li,et al.  Reno: regularized non-parametric analysis of protein lysate array data , 2012, Bioinform..

[21]  M. A. Bopp,et al.  Zeptosens' protein microarrays: A novel high performance microarray platform for low abundance protein analysis , 2002, Proteomics.

[22]  Gordon B Mills,et al.  New era of integrated cancer biomarker discovery using reverse-phase protein arrays. , 2016, Drug metabolism and pharmacokinetics.

[23]  Alexander L. R. Lubbock,et al.  Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer , 2017, BMC Medicine.

[24]  W. Norde,et al.  Spot morphology of non-contact printed protein molecules on non-porous substrates with a range of hydrophobicities. , 2013, The Analyst.

[25]  N. Sata,et al.  Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray , 2011, Cancer science.

[26]  Yuan Ji,et al.  Sparse Bayesian graphical models for RPPA time course data , 2012, Proceedings 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS).

[27]  Ioan Tabus,et al.  Robust estimation of protein expression ratios with lysate microarray technology , 2005, Bioinform..

[28]  C. Lindskog,et al.  Enhanced validation of antibodies for research applications , 2018, Nature Communications.

[29]  M. Gehrmann,et al.  Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate , 2019, Proteomics. Clinical applications.

[30]  Mohammad Fallahi-Sichani,et al.  Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis , 2015 .

[31]  G. Mills,et al.  Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery , 2018, Nature Communications.

[32]  P. V. van Diest,et al.  E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer , 2018, Scientific Reports.

[33]  Andrew Emili,et al.  Panomics for Precision Medicine. , 2018, Trends in molecular medicine.

[34]  Marcus Oswald,et al.  Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery. , 2014, Biochimica et biophysica acta.

[35]  Stephen R Master,et al.  Diagnostic challenges for multiplexed protein microarrays. , 2006, Drug discovery today.

[36]  A. Welm,et al.  mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential , 2018, npj Breast Cancer.

[37]  Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors , 2017, Breast Cancer Research.

[38]  Li Ding,et al.  Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics , 2018, Cell.

[39]  B. Stillman,et al.  FAST slides: a novel surface for microarrays. , 2000, BioTechniques.

[40]  John N. Weinstein,et al.  Development of a robust classifier for quality control of reverse-phase protein arrays , 2015, Bioinform..

[41]  Duncan Hall,et al.  Inkjet printing for the production of protein microarrays. , 2011, Methods in molecular biology.

[42]  E. Petricoin,et al.  Reverse Phase Protein Microarrays. , 2017, Methods in molecular biology.

[43]  Adam Byron,et al.  Clustering and Network Analysis of Reverse Phase Protein Array Data. , 2017, Methods in molecular biology.

[44]  Xuming He,et al.  Non-parametric quantification of protein lysate arrays , 2007, Bioinform..

[45]  G. Mills,et al.  A Comprehensive Comparison of Normalization Methods for Loading Control and Variance Stabilization of Reverse-Phase Protein Array Data , 2014, Cancer informatics.

[46]  G. Mills,et al.  Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro , 2018, BMC Cancer.

[47]  Xiaobo Zhou,et al.  Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach , 2014, Bioinform..

[48]  E. Petricoin,et al.  Signal pathway profiling of prostate cancer using reverse phase protein arrays , 2003, Proteomics.

[49]  Dalila Boughaci,et al.  Discriminate the response of Acute Myeloid Leukemia patients to treatment by using proteomics data and Answer Set Programming , 2018, BMC Bioinformatics.

[50]  George G Klee,et al.  Antibody-based protein multiplex platforms: technical and operational challenges. , 2010, Clinical chemistry.

[51]  Chris Sander,et al.  Spatial Normalization of Reverse Phase Protein Array Data , 2014, PloS one.

[52]  Li Liu,et al.  A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis , 2016, PLoS Comput. Biol..

[53]  Chin-Rang Yang,et al.  Deep proteomic profiling of vasopressin-sensitive collecting duct cells. I. Virtual Western blots and molecular weight distributions. , 2015, American journal of physiology. Cell physiology.

[54]  O. Mariani,et al.  Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma , 2017, British Journal of Cancer.

[55]  Richard Bruch,et al.  Multiplexed Point-of-Care Testing – xPOCT , 2017, Trends in biotechnology.

[56]  N. Carragher,et al.  Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma , 2015, Cancer cell.

[57]  Jan L.A. Voskuil,et al.  The challenges with the validation of research antibodies , 2017, F1000Research.

[58]  E. Petricoin,et al.  Innovations in Clinical Trial Design in the Era of Molecular Profiling. , 2017, Methods in molecular biology.

[59]  Brian B Haab,et al.  Antibody Arrays in Cancer Research , 2005, Molecular & Cellular Proteomics.

[60]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[61]  Yaping Zong,et al.  Forward-phase and reverse-phase protein microarray. , 2007, Methods in molecular biology.

[62]  V. Espina,et al.  Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine , 2014, Molecular Diagnosis & Therapy.

[63]  G. Hutter,et al.  Reverse phase protein arrays enable glioblastoma molecular subtyping , 2017, Journal of Neuro-Oncology.

[64]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[65]  Satoshi Nishizuka,et al.  Protein and lysate array technologies in cancer research. , 2008, Biotechnology advances.

[66]  Yiling Lu,et al.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.

[67]  Li Zhang,et al.  Modified SuperCurve Method for Analysis of Reverse-Phase Protein Array Data , 2015, J. Comput. Biol..

[68]  M. Rubin,et al.  Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. , 2009, Journal of proteome research.

[69]  Richard D. Smith,et al.  Moonshot Objectives: Catalyze New Scientific Breakthroughs—Proteogenomics , 2018, Cancer journal.

[70]  C. Creighton,et al.  Reverse phase protein arrays in signaling pathways: a data integration perspective , 2015, Drug design, development and therapy.

[71]  Simon L Goodman,et al.  The path to VICTORy – a beginner's guide to success using commercial research antibodies , 2018, Journal of Cell Science.

[72]  Jingchun Zhu,et al.  Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report , 2014, Molecular & Cellular Proteomics.

[73]  Li Zhang,et al.  Serial dilution curve: a new method for analysis of reverse phase protein array data , 2009, Bioinform..

[74]  Doriano Fabbro,et al.  Tracing pathway activities with kinase inhibitors and reverse phase protein arrays , 2009, Proteomics. Clinical applications.

[75]  Claude Ricks,et al.  Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies , 2007, Expert review of molecular diagnostics.

[76]  Karl-Friedrich Becker,et al.  Reverse Phase Protein Arrays—Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use , 2015, Microarrays.

[77]  Mads Thomassen,et al.  Microarray R-based analysis of complex lysate experiments with MIRACLE , 2014, Bioinform..

[78]  Adam Byron,et al.  Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies , 2019, Scientific Reports.

[79]  E. Petricoin,et al.  Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. , 2011, Journal of proteome research.

[80]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[81]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[82]  G. Mills,et al.  AKT isoform-specific expression and activation across cancer lineages , 2018, BMC cancer.

[83]  C. Schmidt,et al.  Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs , 2012, Oncogenesis.

[84]  S. Uhlmann,et al.  Utilization of RNAi to validate antibodies for reverse phase protein arrays. , 2011, Methods in molecular biology.

[85]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[86]  E. Jaffe,et al.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.

[87]  Alan D. Stern,et al.  Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array , 2017, bioRxiv.

[88]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[89]  Kevin R. Coombes,et al.  Variable slope normalization of reverse phase protein arrays , 2009, Bioinform..

[90]  S. Wiemann,et al.  Functional Proteomics of Breast Cancer Metabolism Identifies GLUL as Responder during Hypoxic Adaptation. , 2019, Journal of proteome research.

[91]  Henry Rodriguez,et al.  Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing , 2018, Cell.

[92]  Emmanuel Barillot,et al.  NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes Reverse Phase Protein Array Data , 2012, PloS one.

[93]  N. Carragher,et al.  Reverse Phase Protein Arrays and Drug Discovery. , 2017, Methods in molecular biology.

[94]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[95]  T. Beißbarth,et al.  Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery , 2015, Microarrays.

[96]  Ioan Tabus,et al.  Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays , 2006, Proteomics.

[97]  K. Coombes,et al.  A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.

[98]  P. Guldberg,et al.  Towards discovery‐driven translational research in breast cancer , 2004, The FEBS journal.

[99]  M. Masuda,et al.  Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. , 2015, Biochimica et biophysica acta.

[100]  Tuula A Nyman,et al.  A high-throughput pipeline for validation of antibodies , 2018, Nature Methods.